Key result
DPP-4 inhibition did not increase the composite of CV death, non-fatal MI, or non-fatal stroke vs placebo, but increased acute pancreatitis risk.
Meta-Analysis (n=36,543)
Placebo-controlled
Randomized controlled trials
Answers are grounded in this paper and cite their sources.
The full licensing of dipeptidyl peptidase-4 (DPP-4) inhibitors in the USA and Europe requires demonstration of cardiovascular (CV) safety with an upper boundary of harm of <30%. We report a total of 3334 CV events during 86,716 person-years of follow-up in 36,543 patients, when combining data from three trials with formal and prospectively assessed endpoints. Fixed-effect meta-analysis showed that, compared with placebo, DPP-4 inhibition did not increase the upper boundary of risk for the composite endpoint, nor for any individual component by >30%. Relative risks (RRs) were: 0.99 [confidence interval (CI) 0.93-1.06] for composite CV-specific death, non-fatal myocardial infarction (MI) and non-fatal stroke; 1.01 (CI 0.91-1.12) for CV-specific death; 0.98 (CI 0.89-1.09) for non-fatal MI; and 1.00 (CI 0.86-1.16) for non-fatal stroke. The risk of acute pancreatitis was increased (RR 1.79; CI 1.13-2.81), equating to 5.5 extra cases/10,000 patients/year (weighted mean) and a number needed to harm of 1940/year. These data provide reassurance about the safety of DPP-4 inhibitors with regard to individual atherothrombotic events and a safety signal for pancreatitis.
No takes yet. Share an insight, caveat, or question.
Dehbi et al. (2015) reported a meta-analysis. Dipeptidyl peptidase-4 (DPP-4) inhibitors vs. Placebo was evaluated on Composite of cardiovascular-specific death, non-fatal myocardial infarction, and non-fatal stroke (RR 0.99, 95% CI 0.93-1.06). DPP-4 inhibition did not increase the composite of CV death, non-fatal MI, or non-fatal stroke vs placebo, but increased acute pancreatitis risk.
Synapse has enriched 10 related papers. Consider them for comparative context: